1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Issue 4 (April 2020) Authors: Swain, Sandra M; Miles, David; Kim, Sung-Bae; Im, Young-Hyuck; Im, Seock-Ah; Semiglazov, Vladimir; Ciruelos, Eva; Schneeweiss, Andreas; Loi, Sherene; Monturus, Estefanía; Clark, Emma; Knott, Adam; Restuccia, Eleonora; Benyunes, Mark C; Cortés, Javier Journal: Lancet oncology Issue: Volume 21:Issue 4(2020) Page Start: 519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗